Every week, dozens of health-related information circulate on social networks, institutional websites, and mainstream media. Some announce a real health risk, while others relay a preliminary result taken out of context. Distinguishing what deserves your attention from what generates unnecessary noise requires a few simple guidelines.
Reliable health news or just buzz: criteria to check before sharing
Have you ever seen an alarming headline about a medication or a virus, only to find out a few days later that the information was nuanced or even denied? This scenario repeats itself because the dissemination chain shortens the original message.
A first reflex is to identify the primary source. Data published by Santé publique France or by the ANSM is based on a documented surveillance protocol. A figure relayed by an anonymous account on a social network is not.
The second criterion concerns the level of evidence. An official recommendation (for example, an update to the compassionate use framework) has gone through several validation stages. A result from a single cohort, even published in a recognized journal, remains preliminary.
Regularly following the news on Portail de la Santé allows you to find this information already contextualized, which avoids navigating between several institutional websites to cross-check the same topic.
- Check the issuer: health agency, ministry, scientific society, or personal blog without references?
- Look at the date: a three-year-old study relayed as “new” loses its timeliness.
- Read beyond the headline: the body of the article almost always nuances what the headline dramatizes.
- Look for contradiction: if no expert tempers the announcement, it is often because no one has examined it yet.
Flu, Covid-19, and respiratory infections: assessment of the 2025-2026 season
The 2025-2026 flu season marked a turning point due to its intensity. Santé publique France reports nearly 115,000 emergency room visits for flu-like syndrome, about 1,600 clustered episodes in medical-social establishments, and an estimated excess mortality of 12,140 deaths. These figures make it one of the most severe seasons since 2011.
Covid-19, on the other hand, circulated quietly during the same winter. SARS-CoV-2 did not generate a notable impact on healthcare utilization, unlike the flu, which heavily mobilized emergency services.
This inversion of visibility between the two viruses illustrates a phenomenon to remember: the dominant health risk changes from season to season. Focusing all your vigilance on a single pathogen means ignoring the one that, that year, fills the hospital services.
What this changes for the next season
Winter vaccination campaigns target both flu and Covid-19. After such a heavy flu season, health authorities may emphasize the flu vaccine more for vulnerable populations (elderly people, immunocompromised patients, residents of medical-social establishments).
Medication supply tensions: a permanent issue
Medication shortages are no longer isolated incidents. The ANSM has asked laboratories to strengthen their supplies of duloxetine, a widely prescribed antidepressant. It has also reported tensions on Verkazia, an eye drop used in pediatric ophthalmology, recommending that this treatment be reserved for children and adolescents.
Why do these tensions occur so often? The manufacturing of active ingredients is concentrated in a small number of industrial sites, often located outside Europe. A production incident, a spike in demand, or a logistical problem is enough to create a domino effect throughout the chain.
For the patients concerned, two reflexes help limit the impact:
- Quickly report any supply difficulties to your pharmacist, who can contact other wholesalers or suggest a validated alternative.
- Do not stockpile excessively, as individual overstocking worsens the collective shortage.
- Consult the ANSM website, which publishes the updated list of medications under tension with associated recommendations.
Compassionate access: expanded treatments for serious illnesses
Compassionate access allows for the prescription of a medication outside its usual authorization when no alternative exists for a patient with a serious illness. This mechanism has undergone several recent changes.
Between September and October 2026, the ANSM established or modified compassionate use frameworks for several specialties: Venclyxto in relapsed AL amyloidosis, Blincyto in certain pediatric acute lymphoblastic leukemias, and Lutathera in several advanced neuroendocrine tumors.
In practical terms, this means that patients who no longer respond to standard treatments can now access these molecules in a regulated framework, without waiting for an extension of marketing authorization.
How to follow these decisions
Each compassionate access decision is published on the ANSM website with the name of the medication, the relevant indication, and the prescription conditions. These publications often go unnoticed by the general public, even though they directly concern patients and their families.
For healthcare professionals, regularly checking these updates helps avoid missing out on a newly available therapeutic option.
Drug prices and health sovereignty: ongoing arbitration
The drug policy in France is undergoing a phase of redefinition. The challenge is to find a balance between three sometimes contradictory objectives: funding therapeutic innovation, relocating production, and controlling health insurance expenditures.
The state and the pharmaceutical sector have engaged in discussions on a new framework agreement concerning drug prices. This type of negotiation determines the amount reimbursed by Social Security and, by extension, the ability of laboratories to invest in research or maintain manufacturing sites in the territory.
This debate remains technical, but its consequences are direct: a medication whose negotiated price is too low may disappear from the French market if the laboratory deems commercialization unprofitable. Conversely, a price that is too high weighs on the collective budget.
Staying informed on these topics means understanding why some treatments become difficult to find in pharmacies and why others take months to become available after their European authorization. The next winter season will again test the robustness of these arbitrations.
